The National Comprehensive Cancer Network (NCCN) has updated the NCCN Clinical Practice Guidelines in Oncology™ for Kidney Cancer to reflect March 30 Food and Drug Administration (FDA) approval of everolimas (Afinitor®, Novartis) for advanced renal cell carcinoma.
(more…)
April 30th, 2009